I always find it amusing to have this discussion, even with my colleagues and friends from the pharmaceutical industry, that a product that's a generic product, produced in this country, that's labelled differently, that looks different, that's totally, for all intents and purposes, different, first of all, is going to make its way back to a market of people—we're talking HIV/AIDS in this case—who really have.... We don't have an access issue in this country. We've put in place everything that needs to be in place to ensure that people are either covered privately or through public plans.
So what we're saying is that these drugs would then somehow come into our provincial formulary programs and be dispersed somehow through our pharmacies at a cost of nothing because our patients don't pay. I don't know where this is going to come back into Canada. And the same thing holds true for Europe, where many of the programs are similar to those in Canada.
But more importantly, access to drugs for HIV/AIDS in the United States, where we keep saying that there'd be a real potential for abuse in that market, when we're talking HIV/AIDS, really, every single person with HIV/AIDS in the United States of America has access to free antiretroviral drugs. I have a patient who just moved this week, who is so happy he's going to get his free meds there, because as a businessman up here in Canada he had a co-payment with his insurance company of 20%.
I think that's a bit of smoke and mirrors, in terms of having these drugs come back. I think there's real potential for these drugs to travel across borders in resource-limited settings. I think that's a true possibility that could exist, but not back to northern markets.